(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 3.6MM | +45% |
Gross Profit | 587.3K | -73% |
Cost Of Revenue | 3MM | - |
Operating Income | -11.8MM | +32% |
Operating Expenses | 12.4MM | +11% |
Net Income | -14.7MM | - |
R&D | 6.2MM | +7% |
G&A | 4.4MM | +40% |
Marketing | 1.5MM | -20% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address at the 5th Annual MarketsandMarkets conference in London, Company CEO Dwight Egan shared an update on the new manufacturing facilities in Salt Lake City, Utah and in Ranoli, India, including announcing the grand opening of the new Utah facility next month.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, England.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Co-Diagnostics ( NASDAQ:CODX ) Full Year 2023 Results Key Financial Results Net loss: US$35.3m (loss widened by 148...
Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2023 Earnings Call Transcript March 14, 2024 Co-Diagnostics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2023 Earnings Conference Call. All participants will […]
Q4 2023 Co-Diagnostics Inc Earnings Call
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2023 financial results on Thursday, March 14, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwigh
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the list of events it has chosen to exhibit at or participate in during February, 2024, and which strategically align with the Company's vision.